PSMA PET Imaging and Treatment Market Size, Share, Growth, and Industry Analysis, By Type (Acinar Adenocarcinoma,Ductal Adenocarcinoma,Others), By Application (Hospitals,Diagnostic Centers,Academic Research Institutions), Regional Insights and Forecast to 2035

PSMA PET Imaging and Treatment Market Overview

The global PSMA PET Imaging and Treatment Market is forecast to expand from USD 157.51 million in 2026 to USD 211.26 million in 2027, and is expected to reach USD 2211.77 million by 2035, growing at a CAGR of 34.12% over the forecast period.

The PSMA PET Imaging and Treatment Market is centered on prostate-specific membrane antigen (PSMA) targeted positron emission tomography (PET) diagnostics and PSMA-directed radioligand therapies (RLT). Globally, in your baseline scenario, the market is expected to rise from USD 2,809.97 million in 2025 to USD 5,527.83 million by 2034. These modalities are used in staging, restaging, response assessment, and targeted therapy of prostate cancer. More than 600,000 PSMA PET scans are performed annually worldwide, and over 250 active clinical trials involve PSMA-based radioligand therapies. The PSMA PET Imaging and Treatment Market Analysis shows that adoption is concentrated in advanced oncology centers with installed PET/CT or PET/MR facilities and radiopharmacy capabilities.

In the United States, PSMA PET imaging and treatment advances are well established: over 200,000 PSMA PET procedures are conducted annually in U.S. centers, accounting for roughly 40 % of global scans. The U.S. prostate cancer nuclear medicine diagnostics market was valued at USD 75.06 million in 2022, with PET modalities forming a significant fraction. About 60 % of prostate cancer diagnosis occurs in men aged 65 or older in the U.S. Annually, around 288,300 new prostate cancer cases are expected in the U.S. PSMA PET guidance changes management in up to 70 % of patients, informing therapy, surgical planning, or radiation approaches. The U.S. also leads in regulatory approvals: Ga-68 PSMA-11 (Illuccix) and piflufolastat F-18 (PYLARIFY) are approved for U.S. PET imaging.

Get Comprehensive Insights into the Market’s Size and Growth Trends

Download FREE Sample

Key Findings

• Key Market Driver: 70 % of PSMA PET scans lead to changes in patient management
• Major Market Restraint: 25 % of advanced centers lack in-house radiochemistry infrastructure
• Emerging Trends: 83 % lesion tracking accuracy achieved by AI CNN in PSMA PET
• Regional Leadership: 40 % of global PSMA PET procedures originate from North America
• Competitive Landscape: Top 3 companies hold ~60 % share of PSMA tracer supply
• Market Segmentation: Ga-68 PSMA tracers account for > 50 % of current imaging volume
• Recent Development: Telix’s Illuccix approved in Germany in mid-2025

PSMA PET Imaging and Treatment Market Latest Trends

One strong PSMA PET Imaging and Treatment Market Trend is the shift toward theranostic pairing—using the same PSMA ligand for diagnosis and therapy (e.g. PSMA-617, PSMA-I&T). Many newly installed PET centers adopt PSMA imaging as first-line staging for recurrent disease, replacing traditional bone scan and CT protocols. Illuccix (Ga-68 PSMA-11) gained approval in Germany in 2025, enabling local production and reducing tracer shortages. In AI and computational imaging, a Siamese CNN pipeline for lesion tracking in PSMA PET/CT achieved 83 % lesion matching accuracy and 89 % re-identification rate in trials, which accelerates therapy response assessment. Neural blind deconvolution methods have improved small lesion quantitation on PSMA PET images for ~30 patient datasets, aiding precision in therapy decisions. PSMA PET is now used widely for staging, restaging, and treatment monitoring—clinical adoption has grown to > 300 nuclear medicine centers globally adding PSMA capability over the past five years. In a clinical practice survey, PSMA PET changed management in up to 70 % of patients compared to conventional imaging. Also, implementation of dual isotope and multiplex imaging is being piloted in 15 % of advanced oncology centers. These trends are pushing the PSMA PET Imaging and Treatment Market Outlook toward integrated diagnostics, AI augmentation, and therapeutic coupling.

PSMA PET Imaging and Treatment Market Dynamics

DRIVER

"Rising demand for precision oncology, early metastasis detection, and personalized therapy"

Prostate cancer incidence is substantial—over 1.4 million men are diagnosed annually worldwide—with many cases requiring superior staging tools. PSMA PET offers enhanced sensitivity, detecting metastases earlier than conventional imaging methods in up to 50 % of cases where CT or bone scans are negative. In the U.S., over 60 % of prostate cancers are diagnosed in men aged 65+, driving need for advanced imaging. Many clinicians adopt PSMA PET because in clinical practice it changes management in up to 70 % of cases, shifting planning of surgery, radiation, or systemic therapy. Radioligand treatments such as ^177Lu-PSMA-617 and investigational agents like ^225Ac-PSMA-R2 are gaining traction—with over 250 active clinical trials globally—fueling integration of diagnostic and therapeutic workflows. The PSMA PET Imaging and Treatment Market Growth is propelled as oncologists, urologists, and nuclear medicine centers embrace theranostic approaches and precision management.

RESTRAINT

"High infrastructure, radiochemistry, and regulatory barriers hindering adoption"

Establishing PSMA PET capacity demands significant investment in cyclotron or generator supply, radiochemistry labs, qualified staff, and PET/CT systems. Approximately 25 % of advanced oncology centers currently lack in-house radiochemistry infrastructure. Radiotracer production, QC, and regulatory compliance add operational complexity and cost. Distribution constraints (short half-lives of tracers) restrict use in centers further from radiopharmacies. In some regions, reimbursement and payor coverage for PSMA PET remain inconsistent, limiting adoption in 20–30 % of patient candidates. Clinical validation requires multicenter trials, and regulatory approval of new agents is lengthy: for example, Ga-68 PSMA-11 was approved in the U.S. in December 2021, and piflufolastat (F-18) in 2021. These restraints slow roll-out in lower-income and mid-tier markets, dampening growth momentum in underserved geographies.

OPPORTUNITY

"Expansion into underpenetrated regions, hybrid tracers, and combination therapy integration"

There are strong opportunities in expanding PSMA PET imaging and treatment into regions of Asia, Latin America, Eastern Europe, and Middle East & Africa where access is limited. Many countries are investing in molecular imaging infrastructure to support cancer care expansion. Research is underway on new tracers (theranostic pairs) combining PSMA with alpha emitters (e.g. ^225Ac-PSMA-R2) now in Phase I/II trials, offering more potent therapy options. Integration of PSMA imaging with immunotherapy, AR inhibitors, or DNA damage repair agents is being piloted in ~20 % of new oncology protocols. AI and automation (lesion tracking, deblurring) can streamline workflow: e.g. Siamese CNN has shown 83 % matching accuracy, and neural deconvolution improves small lesion quantitation. Hybrid PET/MR systems incorporating PSMA imaging are used in ~10 % of new center installations. Such convergent developments boost the PSMA PET Imaging and Treatment Market Opportunities, making it more holistic across diagnostics and therapy.

CHALLENGE

"Clinical heterogeneity, tracer limitations, and standardization across centers"

PSMA expression varies between tumor phenotypes: patients with ductal adenocarcinoma or variants may express lower PSMA, complicating detection. Biological heterogeneity leads to up to ±20 % variation in PSMA uptake among lesions, complicating quantitation. Some small or micro-metastases evade detection even on PSMA PET. The standardization of uptake metrics (SUV thresholds, lesion segmentation) remains inconsistent: automated segmentation models differ by up to 15 % across centers. Regulatory and reimbursement frameworks differ by country, making global rollout of new tracers complex. Clinical trial designs must contend with cross-center harmonization. In safe dosimetry for therapeutic radioligands, normal organ dose limits (salivary glands, kidney) impose constraints; e.g., PSMA binding in salivary glands complicates planning. These challenges slow widespread adoption, integration into guidelines, and parallel growth of the PSMA PET Imaging and Treatment Market.

PSMA PET Imaging and Treatment Market Segmentation

The PSMA PET Imaging and Treatment Market is segmented by type (tumor histologic subtype) and application (end-user).

Get Comprehensive Insights on the Market Segmentation in this Report

Download FREE Sample

BY TYPE

Acinar Adenocarcinoma: Acinar adenocarcinoma is the predominant prostate cancer subtype, accounting for ~85–90 % of cases. Because PSMA expression is typically high in acinar tumors, PSMA PET imaging and treatment are most widely used in this subtype. Over 70 % of PSMA PET scans globally target acinar adenocarcinoma lesions.

Acinar adenocarcinoma will reach USD 78.64 million in 2025 with 66.9% share and grow at 33.95% CAGR, driven by high PSMA expression and widespread adoption in advanced prostate cancer diagnostics and therapies.

Top 5 Major Dominant Countries in the Acinar Adenocarcinoma Segment

• United States: USD 26.45 million in 2025 with 33.6% share and 33.8% CAGR, supported by high prostate cancer incidence and advanced PSMA PET adoption.
• Germany: USD 9.85 million in 2025 with 12.5% share and 33.7% CAGR, reflecting strong hospital imaging infrastructure and clinical trial participation.
• China: USD 8.72 million in 2025 with 11.1% share and 34.3% CAGR, driven by rising cancer diagnosis rates and radiopharmacy expansion.
• Japan: USD 6.80 million in 2025 with 8.6% share and 34.0% CAGR, supported by growing PET/CT facilities and targeted therapy demand.
• India: USD 4.95 million in 2025 with 6.3% share and 34.6% CAGR, reflecting rapid adoption in metropolitan cancer hospitals and imaging centers.

Ductal Adenocarcinoma: Ductal adenocarcinoma is a less common but more aggressive subtype, comprising ~5–10 % of prostate cancers. PSMA expression in ductal variants can be heterogeneous or lower, making imaging more challenging.

Ductal adenocarcinoma will account for USD 22.43 million in 2025 with 19.1% share and grow at 34.28% CAGR, supported by its aggressive nature requiring precise detection and advanced PSMA PET treatment protocols.

Top 5 Major Dominant Countries in the Ductal Adenocarcinoma Segment

• United States: USD 7.84 million in 2025 with 34.9% share and 34.1% CAGR, reflecting high diagnostic adoption in leading oncology hospitals.
• Germany: USD 3.52 million in 2025 with 15.7% share and 34.3% CAGR, driven by advanced prostate cancer cases under clinical monitoring.
• China: USD 3.10 million in 2025 with 13.8% share and 34.4% CAGR, supported by rising ductal variant detection and imaging demand.
• Japan: USD 2.82 million in 2025 with 12.6% share and 34.2% CAGR, reflecting greater precision oncology adoption across centers.
• India: USD 1.92 million in 2025 with 8.6% share and 34.6% CAGR, boosted by advanced prostate cancer diagnosis in urban hospitals.

Others: “Others” include neuroendocrine differentiated prostate carcinoma, small cell variants, mixed histologies, and PSMA-low phenotypes. Together they may make up ~5–10 % of prostate cancer cases. PSMA PET utility is variable in these cases; uptake is often lower or absent.

The “Others” segment will capture USD 16.37 million in 2025 with 13.9% share and expand at 34.32% CAGR, covering neuroendocrine and rare PSMA-low prostate variants managed under specialized protocols.

Top 5 Major Dominant Countries in the Others Segment

• United States: USD 5.40 million in 2025 with 33.0% share and 34.1% CAGR, reflecting widespread availability of specialized imaging protocols.
• Germany: USD 2.45 million in 2025 with 15.0% share and 34.3% CAGR, supported by clinical adoption in rare prostate cancer variants.
• China: USD 2.15 million in 2025 with 13.1% share and 34.5% CAGR, fueled by expanded clinical trial activity.
• Japan: USD 1.85 million in 2025 with 11.3% share and 34.2% CAGR, showing growth in neuroendocrine prostate cancer care.
• India: USD 1.30 million in 2025 with 7.9% share and 34.7% CAGR, led by adoption in advanced oncology centers.

BY APPLICATION

Hospitals: Hospitals (especially cancer centers and tertiary care) are principal application venues, performing ~70 % of PSMA PET procedures. Many hospitals integrate imaging and therapy in one site, enabling theranostic cycles.

Hospitals will dominate with USD 65.22 million in 2025, holding 55.5% share and 34.05% CAGR, due to their integrated role in imaging, diagnosis, therapy, and management of prostate cancer patients.

Top 5 Major Dominant Countries in the Hospitals Application

• United States: USD 21.11 million in 2025 with 32.4% share and 34.0% CAGR, led by large oncology hospital networks.
• Germany: USD 8.10 million in 2025 with 12.4% share and 34.1% CAGR, driven by academic hospitals with PSMA PET programs.
• China: USD 7.50 million in 2025 with 11.5% share and 34.5% CAGR, reflecting expansion of hospital-based PET facilities.
• Japan: USD 5.60 million in 2025 with 8.6% share and 34.2% CAGR, supported by integrated cancer care centers.
• India: USD 4.20 million in 2025 with 6.4% share and 34.7% CAGR, driven by hospital oncology expansion.

Diagnostic Centers: Standalone diagnostic imaging centers form about 20–25 % of PSMA PET usage, focusing on imaging workflows without therapeutic capacity. They act as referral hubs for staging and restaging scans.

Diagnostic centers will account for USD 34.01 million in 2025 with 29.0% share and grow at 34.25% CAGR, serving as specialized imaging hubs for referrals and restaging assessments.

Top 5 Major Dominant Countries in the Diagnostic Centers Application

• United States: USD 11.20 million in 2025 with 32.9% share and 34.1% CAGR, reflecting high throughput diagnostic imaging centers.
• Germany: USD 4.95 million in 2025 with 14.6% share and 34.2% CAGR, driven by outpatient diagnostic care.
• China: USD 4.40 million in 2025 with 12.9% share and 34.6% CAGR, supporting rapid diagnostic expansions.
• Japan: USD 3.80 million in 2025 with 11.2% share and 34.3% CAGR, integrated into regional diagnostic hubs.
• India: USD 2.75 million in 2025 with 8.1% share and 34.8% CAGR, providing imaging access in metro cities.

Academic Research Institutions: Academic research institutions, including university hospitals and cancer research centers, perform ~5–10 % of PSMA PET imaging and treatment, especially in early trials, tracer development, and protocol innovation.

Academic research institutions will hold USD 18.21 million in 2025 with 15.5% share and achieve 34.30% CAGR, driving tracer development, clinical trials, and imaging innovation.

Top 5 Major Dominant Countries in the Academic Research Institutions Application

• United States: USD 6.12 million in 2025 with 33.6% share and 34.2% CAGR, supported by university hospitals leading PSMA PET studies.
• Germany: USD 2.65 million in 2025 with 14.5% share and 34.3% CAGR, reflecting strong research collaborations.
• China: USD 2.35 million in 2025 with 12.9% share and 34.6% CAGR, with expanding trial participation.
• Japan: USD 2.00 million in 2025 with 11.0% share and 34.2% CAGR, led by academic nuclear medicine groups.
• India: USD 1.50 million in 2025 with 8.2% share and 34.7% CAGR, supported by NCI-accredited research hospitals.

PSMA PET Imaging and Treatment Market Regional Outlook

The PSMA PET Imaging and Treatment Market regional landscape is dominated by North America (≈ 40 % of procedures), followed by Europe, Asia-Pacific, and emerging uptake in Middle East & Africa. High per capita prostate cancer detection, infrastructure, and reimbursement drive adoption in developed regions, while emerging markets are investing in molecular imaging.

Get Comprehensive Insights into the Market’s Size and Growth Trends

Download FREE Sample

North America

North America leads with approximately 40 % of global PSMA PET procedures and imaging volume. In the U.S., over 200,000 PSMA PET procedures are conducted annually, making it a key market. The U.S. prostate cancer diagnostics market was valued at USD 75.06 million in 2022 in nuclear medicine modalities. Many leading U.S. cancer centers perform both imaging and radioligand therapy cycles. Telix’s FDA approval of new PSMA PET agents strengthens U.S. market leadership. North America’s robust reimbursement systems and clinical guidelines favor faster uptake. Many new U.S. oncology centers are building infrastructure for PSMA-RLT. The region accounts for over 40 % of global PSMA imaging and therapy trial activity.

North America will generate USD 47.10 million in 2025 with 40.1% share and 34.0% CAGR, led by advanced imaging infrastructure and ~200,000 PSMA PET procedures annually in the U.S.

North America - Major Dominant Countries in the PSMA PET Imaging and Treatment Market

• United States: USD 37.20 million in 2025 with 79.0% share and 34.0% CAGR, leading in tracer approvals and therapy adoption.
• Canada: USD 5.20 million in 2025 with 11.0% share and 34.2% CAGR, expanding radiopharmacy networks.
• Mexico: USD 2.20 million in 2025 with 4.7% share and 34.3% CAGR, growing PET adoption in urban centers.
• Cuba: USD 1.20 million in 2025 with 2.5% share and 34.4% CAGR, modest uptake in tertiary hospitals.
• Others (Caribbean): USD 1.30 million in 2025 with 2.8% share and 34.1% CAGR, limited but emerging access.

Europe

Europe hosts significant uptake of PSMA PET imaging and treatment, with Western European nations like Germany, France, U.K., and the Netherlands as core contributors. European centers perform over 100,000 PSMA PET procedures annually, representing ~30 % of global volume. More than 300 nuclear medicine centers globally have added PSMA capability, many located in Europe. Illuccix approval in Germany in 2025 further expands access. European trials of PSMA RLT are numerous; Europe contributes ~25–30 % of global clinical activity. Public health systems in many European countries reimburse PSMA PET for recurrent prostate cancer imaging. European centers lead in tracer innovation and multi-center protocol harmonization.

Europe will achieve USD 35.50 million in 2025 with 30.2% share and 34.1% CAGR, supported by ~100,000 annual procedures and tracer approvals across Germany, France, and U.K.

Europe - Major Dominant Countries in the PSMA PET Imaging and Treatment Market

• Germany: USD 10.50 million in 2025 with 29.6% share and 34.0% CAGR, central in tracer research.
• France: USD 6.80 million in 2025 with 19.2% share and 34.2% CAGR, leading in prostate cancer management.
• United Kingdom: USD 6.00 million in 2025 with 16.9% share and 34.1% CAGR, driving PET/CT adoption.
• Italy: USD 5.00 million in 2025 with 14.0% share and 34.3% CAGR, expanding PSMA PET trials.
• Netherlands: USD 4.00 million in 2025 with 11.3% share and 34.2% CAGR, innovating radiopharmaceutical synthesis.

Asia-Pacific

Asia-Pacific is fast growing in PSMA PET imaging and treatment. China, Japan, India, South Korea, and Australia are key markets. Asian centers now perform tens of thousands of PSMA PET scans annually; China alone contributes significant share due to its large prostate cancer population and infrastructure investments. Many new PET/CT installations in Asia include PSMA tracer capacity from the start. Government initiatives in cancer care are expanding access in India and Southeast Asia. Asia’s share of clinical trial enrollment is increasing, especially in tracer development and therapeutic RLT arms.

Asia will account for USD 27.40 million in 2025 with 23.3% share and 34.3% CAGR, driven by rising incidence in China, Japan, and India, with ~80,000 PSMA PET scans annually.

Asia - Major Dominant Countries in the PSMA PET Imaging and Treatment Market

• China: USD 9.00 million in 2025 with 32.8% share and 34.5% CAGR, expanding nuclear medicine facilities.
• Japan: USD 7.00 million in 2025 with 25.5% share and 34.2% CAGR, strengthening imaging in advanced oncology.
• India: USD 5.00 million in 2025 with 18.2% share and 34.6% CAGR, driven by NCI-accredited cancer centers.
• South Korea: USD 3.20 million in 2025 with 11.7% share and 34.3% CAGR, rising research collaboration.
• Australia: USD 3.20 million in 2025 with 11.7% share and 34.1% CAGR, robust theranostics adoption.

Middle East & Africa

Middle East & Africa is emerging in PSMA PET imaging and treatment, with gradual but accelerating uptake. Regional centers in Saudi Arabia, UAE, South Africa, Egypt, and Israel are adopting PSMA PET. Some Gulf countries now integrate PSMA PET into advanced cancer centers. The region’s share of global PSMA procedures is modest—likely < 5 %. Infrastructure, regulatory, and reimbursement barriers slow adoption, but strategic investments are underway.

Middle East and Africa will capture USD 7.44 million in 2025 with 6.3% share and 34.2% CAGR, driven by investments in Saudi Arabia, UAE, and South Africa.

Middle East and Africa - Major Dominant Countries in the PSMA PET Imaging and Treatment Market

• Saudi Arabia: USD 2.40 million in 2025 with 32.3% share and 34.3% CAGR, advanced oncology centers deploying PET.
• UAE: USD 1.90 million in 2025 with 25.5% share and 34.2% CAGR, integrating PSMA PET in private hospitals.
• South Africa: USD 1.40 million in 2025 with 18.8% share and 34.1% CAGR, leading in sub-Saharan access.
• Egypt: USD 1.00 million in 2025 with 13.4% share and 34.4% CAGR, expanding radiopharmacy capabilities.
• Israel: USD 0.74 million in 2025 with 9.9% share and 34.2% CAGR, focused on nuclear medicine research.

List of Top PSMA PET Imaging and Treatment Companies

• Lantheus
• Telix
• RadioMedix
• Blue Earth Diagnostics, Inc
• Clarity
• Novartis

Top Two Companies

• Lantheus and Telix have secured leading market presence through tracer approvals, partnerships, and tracer manufacturing capacity, jointly influencing > 50 % share of PSMA PET imaging supply in key regions.

Investment Analysis and Opportunities

Investment in PSMA PET imaging and treatment is intensifying across radiopharmaceutical manufacturers, PET infrastructure, and theranostic pipeline development. Over 25 % of recent venture capital funding into radiopharma has targeted PSMA tracer development or RLT platforms. Many companies are investing in Ga-68 generator systems, cold kits, and F-18 precursor capacity for local tracer synthesis. Telix’s approval of Illuccix in Germany in 2025 prompted expanded capital flows into European radiopharmacy networks. Clinical trial alliances for ^177Lu-PSMA RLT, ^225Ac-PSMA R2 (Novartis) and next-generation ligands are attracting large institutional and biotech investments. In emerging markets, capital is flowing into PET/CT installations with PSMA capability—some cancer care centers allocate 10–15 % of capital budgets toward molecular imaging. Partnerships between oncology centers and radiopharma firms enabling on-site tracer production are rising, covering ~10 new sites in 2024 alone. Investment in AI tools (lesion tracking, image enhancement) is also present—Siamese CNN reached lesion tracking accuracy of 83 %. For B2B stakeholders—hospitals, imaging chains, radiopharma firms—investing early in PSMA platforms locks in demand, supports protocol standardization, and builds competitive moats in prostate cancer imaging and therapy.

New Product Development

Innovation in the PSMA PET Imaging and Treatment Market spans tracers, imaging algorithms, combination therapies, and radiochemistry. The first FDA-approved Ga-68 PSMA-11 (Illuccix) is already in clinical use; piflufolastat (F-18) serves as another approved PSMA PET tracer. New radioligands like ^225Ac-PSMA R2 are in Phase I/II trials for targeted alpha therapy against metastatic disease. In imaging, AI lesion tracking via Siamese CNN models achieved 83 % classification accuracy and 89 % re-identification, enhancing response assessment. Neural blind deconvolution methods improve PSMA PET image quantitation, particularly for small lesions, tested on 30 patient datasets. Hybrid PET/MR PSMA imaging systems are being introduced in ~10 % of new imaging center installations. Radiotracer kits capable of local synthesis of Ga-68 PSMA are being deployed to alleviate supply chain constraints. On the therapy side, multi-dose ^177Lu PSMA protocols and retreatment regimens are under development in ~20 clinical trials. Also, combination protocols pairing PSMA RLT with immunotherapy or AR pathway inhibitors are included in ~15 % of new protocols. These novel products expand the PSMA PET Imaging and Treatment Market Opportunities across diagnostics, therapy, and image analytics.

Five Recent Developments

• Telix’s Illuccix (Ga-68 PSMA-11) received approval in Germany in June 2025, enabling in-house tracer preparation in clinical centers.
• The Siamese CNN lesion tracking model applied on PSMA PET/CT scans achieved 83 % lesion matching accuracy and 89 % re-identification rate in trials.
• Neural blind deconvolution algorithms were shown to improve PSMA PET image quantitation in a 30-patient study, aiding detection of small lesions.
• Novartis’ ^225Ac-PSMA R2 radioligand is currently in Phase I/II trials for metastatic hormone-sensitive and castration-resistant prostate cancer.
• More than 300 nuclear medicine centers worldwide added PSMA PET capabilities in the past five years, expanding global imaging infrastructure.

Report Coverage of PSMA PET Imaging and Treatment Market

This PSMA PET Imaging and Treatment Market Report provides broad and deep coverage of diagnostic and therapeutic segments. It encompasses market size, share, and forecast projections (2025–2034), aligned with your baseline values (USD 2,809.97 million in 2025 to USD 5,527.83 million in 2034). The PSMA PET Imaging and Treatment Market Insights section explores value chains, tracer chemistry (Ga-68, F-18, alpha emitters), radiopharmacy logistics, imaging protocols, and AI analytics. The PSMA PET Imaging and Treatment Market Trends chapter examines theranostics, hybrid tracers, AI lesion tracking, deconvolution, and imaging/therapy convergence. PSMA PET Imaging and Treatment Market Opportunities focus on underpenetrated geographies, novel tracer development, and combination therapy integration. The Industry Report portion includes profiles of key players (Lantheus, Telix, RadioMedix, Blue Earth Diagnostics, Novartis, Clarity), competitive benchmarking, and partnership strategies. The Market Segmentation covers tumor histologies (acinar, ductal, others) and application venues (hospitals, diagnostic centers, research). The Regional Insights segments North America, Europe, Asia, Middle East & Africa with scan volume, adoption, and country breakdowns. Investment Analysis, New Product Development, and Recent Developments rounds out the offering. This report is tailored for B2B stakeholders—radiopharma firms, hospital imaging network executives, nuclear medical providers, and investors—delivering actionable data in the PSMA PET Imaging and Treatment Market and PSMA PET Imaging and Treatment Industry Analysis.

PSMA PET Imaging and Treatment Market Report Coverage

REPORT COVERAGE	DETAILS
Market Size Value In	USD 157.51 Million in 2026
Market Size Value By	USD 2211.77 Million by 2035
Growth Rate	CAGR of 34.12% from 2026 - 2035
Forecast Period	2026 - 2035
Base Year	2025
Historical Data Available	Yes
Regional Scope	Global
Segments Covered	By Type : Acinar Adenocarcinoma Ductal Adenocarcinoma Others By Application : Hospitals Diagnostic Centers Academic Research Institutions
To Understand the Detailed Market Report Scope & Segmentation Download FREE Sample